Advanced Solid Tumor Clinical Trials in Tucson, Arizona

5 studies are recruiting for advanced solid tumor in Tucson, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

   The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as well as in combination with Investigator's choice of nivolumab or pembrolizumab in patients with advanced solid tumors. VAX014 is a targeted on…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arizona Cancer Center, Tucson, Arizona

   Locations

   8 in total

   Run by

   Vaxiion Therapeutics

   See if you can join NCT05901285 on ClinicalTrials.gov

2. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arizona Cancer Center, Tucson, Arizona

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

3. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

   The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Arizona Cancer Center, Tucson, Arizona

   Locations

   30 in total

   Run by

   Coherus Oncology, Inc.

   See if you can join NCT06657144 on ClinicalTrials.gov

4. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

   This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 to 89

   Site

   The University of Arizona Cancer Center, Tucson, Arizona

   Locations

   57 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT06253130 on ClinicalTrials.gov

5. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Arizona Cancer Center, Tucson, Arizona

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov